encouraging slightly better overall diagnostic performance and practical/ technical advantages in favor of 18F-fluciclovine as compared with the routine tracer. Enrolment and further analyses (region-based/semiquantitative/uni-multivariate-logistic-regression to evaluate predictive factors) are ongoing.
INTRODUCTION AND OBJECTIVES: With current standard cross-sectional imaging (CT or MRI) detection of prostate cancer lesions in patients with biochemical recurrence (BCR) after radical prostatectomy remains challenging, especially at low PSA values. Recently, 68Ga-PSMA PET imaging has been shown to improve detection rates. However, up to now published case series include only a limited number of patients at low PSA values.
METHODS: For this retrospective analysis 272 pts with BCR after radical prostatectomy were extracted from the institutional database who presented with a PSA value from 0.2 up to 1ng/ml at the time of 68Ga-PSMA PET/CT imaging. 68Ga-PSMA PET/CT was evaluated by one experienced reader for lesions suggestive for prostate cancer recurrence and site of suspicious lesions was reported. Patients were grouped according to PSA value, from 0.2 e 0.5ng/mL and from >0.5 e 1.0ng/mL. Primary T-, N-stage, Gleason-Score, D'Amico-Classification, previous local radiation therapy as well as concurrent androgen deprivation therapy (ADT) was correlated to detection rates.
RESULTS: In total, in 54.5 % (73/134) of patients with PSA from 0.2 e 0.5ng/mL and in 76.1% (102/134) of patients with PSA >0.5 e 1.0ng/mL suspicious findings on 68Ga-PSMA PET/CT imaging were noted. Sites of recurrence were local (37.0% and 41.2%), pelvic or retroperitoneal lymph nodes (45.2% and 54.9%), bone (24.7% and 29.4%), supradiaphragmal lymph nodes (6.8% and 6.9%) as well as others (4.1% and 2.0%). In patients with primary locally advanced tumors (pT>3a), primary N+ disease, Gleason-Scores >8, primary higher D'Amico-Classification, previous radiation therapy as well as with concurrent ADT positive findings on 68Ga-PSMA PET/ CT were more likely compared to patients without these characteristics.
CONCLUSIONS: 68Ga-PSMA PET/CT is able to identify sites of recurrent prostate cancer after radical prostatectomy even at low PSA values up to 1ng/ml in a significant number of patients e especially in patients with primary more aggressive tumor characteristics, previous local radiation therapy or concurrent ADT e and thus will very likely present the future imaging technique in these patients. As salvage therapies (local radiation therapy, salvage lymph node dissection or PSMA-radioguided surgery) are most effective at low PSA-levels, early detection of cancerous foci by 68Ga-PSMA PET might even improve oncological results. 
INTRODUCTION AND OBJECTIVES:
The aim of this retrospective study was to evaluate the detection rate of 68Ga-PSMA PET/ CT in a homogeneous patient population with biochemical recurrent prostate cancer defined by Phoenix criteria after external beam radiotherapy (EBRT) or brachytherapy as primary treatment and who had not undergone previous salvage prostatectomy.
METHODS: After screening of our institutional database 118 patients were finally eligible for this retrospective analysis with a median PSA of 6.4 ng/mL (range: 2.2 -158.4 ng/mL). 77 and 41 patients had been treated by EBRT or brachytherapy, respectively. Of the 118 patients, 45 were receiving androgen deprivation therapy (ADT) within at least 6 months prior to 68Ga-PSMA PET/CT. The detection rates were stratified by PSA (2 to <5, 5 to <10 and ¼10 ng/mL). The influence of primary Gleason score at diagnosis and ADT was assessed. Correlations between standardized uptake values (SUV) and Gleason score or ADT in patients with positive findings were analyzed.
RESULTS: 90.7% (107/118) patients showed pathological findings indicative for tumor recurrence in 68Ga-PSMA PET/CT. The detection rates were 81.8% (36/44), 95.3% (41/43) and 96.8% (30/31) for PSA ranges of 2 to <5, 5 to <10 and ¼10 ng/mL, respectively. 68Ga-PSMA PET/CT indicated local recurrence in 68/107 patients (63.5%), only distant lesions in 64/105 patients (59.8%) and local recurrence as well as distant lesions in 25/107 patients (23.4%). The detection rate was significantly higher in patients with ADT (97.7%) vs. without ADT (86.3%, p¼0.0381), but independent from primary Gleason score ¼8 (92.0%) vs. ¼7 (90.2%, p¼0.6346). SUVmax and SUVmean were significantly higher in patients with ADT (p¼0.0025 and 0.0044, respectively) and a clear trend to higher values was observed for patients with Gleason score ¼8 (p¼0.0502 and 0.0514, respectively).
CONCLUSIONS: 68Ga-PSMA PET/CT demonstrates high detection rates in patients with biochemical recurrence of prostate cancer after primary radiation therapy as defined by Phoenix criteria. The detection rate positively correlated to increasing PSA as well as concomitant ADT. 68Ga-PSMA PET/CT enables discrimination of local vs. systemic disease and thus might have a crucial impact on further clinical management. The high observed detection rates even at very low PSA values questions the definition of recurrence by the current Phoenix criteria. A limitation of this study is the lack of histopathological proof in the majority of patients. INTRODUCTION AND OBJECTIVES: US-MRI fusion biopsy (FB) showed that it improves the detection of clinically significant prostate cancer (PCa). A more accurate diagnostic method is desirable to avoid misclassification, which in turn is particularly important in appropriate decision making on treatment for PCa (active surveillance or focal therapy or radical treatment). We aimed to compare the Gleason upgrading (GU) rates and the concordance of the Gleason scores in the biopsy versus final pathology after the surgery in patients who e1188
THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 underwent only TRUS systematic random biopsies versus US-MRI FB for PCa. METHODS: A retrospective analysis of patients 0 prospective collected data that underwent prostate biopsy and subsequent radical prostatectomy were included from January 2011 to June 2016 at our institution. The study cohort was divided into: US-MRI FB (Group A) and only TRUS systematic random biopsy (Group B). US-MRI FB was performed in patients who had a previous MRI with a focal lesion classified by Likert score ! 3, otherwise a TRUS systematic random biopsy was performed. All biopsies and surgical specimens were analyzed by the same uropathologist and MRIs were analyzed by two expert urological radiologists.
RESULTS: 73 men underwent US-MRI FB and 89 TRUS systematic random biopsy. The GU rate was higher in group B (31.5% vs 16.4%; p ¼ 0.027). GU according to Gleason grade pattern was higher in Group B against Group A (40.4% vs 23.3%; p ¼ 0.02). Analyses from separate Gleason grade pattern showed that Gleason score 3+4 presented less GU in group A (24.1% vs 52.6%; p ¼ 0.043)(table 1). The Bland-Altman plot analysis showed a higher bias in Group B compared to group A (-0.27 [-1.40 to 0.86] vs -0.01 [-1.42 to 1.39] ). In the multivariable logistic regression the only independent predictor of GU was the use of TRUS systematic random biopsy (2.64 [1.11 -6.28]; p ¼ 0.024).
CONCLUSIONS: The US-MRI FB appears to be related to a decrease in GU rate and an increase in the concordance between biopsy and final pathology in comparison to TRUS random biopsy, that leads to greater accuracy on diagnosis and better treatment decision.
Source of Funding: None

PD61-05 OUTCOMES OF REPEAT MRI-US FUSION-TARGETED BIOPSY IN MEN WITH INITIALLY LOW RISK OR NEGATIVE FUSION BIOPSY
Xiaosong Meng*, Andrew Rosenkrantz, Fang-Ming Deng, Richard Huang, James Wysock, Marc Bjurlin, William C. Huang, Herbert Lepor, Samir S. Taneja, New York, NY INTRODUCTION AND OBJECTIVES: While the value of MRI-US Fusion-targeted biopsy (MRF-TB) in the identification of occult, clinically significant prostate cancer (csPCa), has been well described, the accuracy of targeting using available fusion platforms is not as clear. As the need for repeat biopsy among men with negative or low risk MRF-TB remains to be defined, we evaluated the outcomes of repeat MRF-TB among men with initially negative or low risk MRF-TB.
METHODS: Between 6/2012 and 9/2016, 1,584 consecutive men undergoing pre-biopsy prostate MRI followed by MRF-TB and systematic biopsy (SB) were enrolled in prospective date registry. 195 men underwent repeat MRI and MRF-TB for continued suspicion of csPCa. 76 men were excluded from analysis due to outside facility or 1.5T MRI, hip implant or interval focal therapy. Upgrade was defined as an increase in Gleason score (GS) from 3+3 to !3+4 or from 3+4 to !4+3 among men with PCa noted on first MRF-TB, or any cancer among men with no cancer on first MRF-TB. Biopsy outcomes were stratified per MRI findings and progression.
RESULTS: 119 men (mean age 65.9AE7.7 years, mean PSA 5.8AE4.5 ng/mL) underwent repeat MRF-TB. The median interval between initial and repeat biopsy was 17.1AE8.9 months. On repeat biopsy, 50% (59) had concordant GS, 17% (20) were downgraded, and 34% (40) were upgraded. Of the 40 upgrades, 42% (17) were due to an increase in GS and 58% (23) were due to newly detected PCa, as illustrated in Table 1 . PI-RADS score was predictive of the likelihood of upgrade on repeat MRF-TB (Table 2) . 53% of men with PI-RADS 4 and 5 demonstrated upgrade on repeat biopsy compared to 26% of men with PI-RADS 3. 82% (9/11) of upgrades in men with PI-RADS 1 and 2 were due to newly detected GS 6 disease.
CONCLUSIONS: 53% of men with PI-RADS 4 and 5 lesions were upgraded on repeat MRF-TB, suggesting a need for repeat sampling among men with low risk or negative MRF-TB and persistent PI-RADS 4 and 5 regions noted on follow-up MRI. Among men with PI-RADS 1 or 2 on repeat imaging, continued observation may be reasonable given the low likelihood (5%) of csPCa on repeat MRF-TB. 
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